An interventional study of Fluid resuscitation in Shock, sponsored by Southeast University, China. Status unknown. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-15.
Sponsored by Southeast University, China · Not applicable, Interventional, and Prevention
Fluid resuscitation is important in shock therapy, but the choice of fluids, especially the choice of crystalloid is under debate. It is said that normal saline is related to hyperchloremia， which might lead to acute kidney injury. Thus the hypothesis of the study is to explicit whether balanced salt solution could reduce the incidence of acute kidney injury when compared with normal saline.
916 studies on the registry are indexed under Shock; 176 are open to participants now.
This study's planned enrollment of 40 is below the median of 77 across 540 interventional studies indexed under Shock.
Browse Shock studies →Southeast University, China is the lead sponsor of 164 studies on the registry; 44 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Shock patients who resuscitated with normal saline were enrolled between June, 2015-June.2016.
Drug: Fluid resuscitation
Shock patients who resuscitated with balanced solution were enrolled after June, 2016.
Drug: Fluid resuscitation
The placebo group is resuscitated with normal saline, the experimental group is resuscitated with balanced fluid.
Incidence of acute kidney injury
Diagnosis of acute kidney injury
Time frame: 28-day
Usage of renal replacement of therapy
Usage of CRRT
Time frame: 28-day
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Southeast University, China